http://www.venturedeal.com/Executives/Kimberly-Salgado-Naryx%20Pharma-Vice%20President-Profile Witryna22 maj 2006 · Naryx is a biopharmaceutical company developing proprietary products for the treatment of chronic sinusitis, one of the most common chronic conditions in the …
SINUSPHARMA Trademark of NARYX PHARMA, INC.. Serial …
Witryna23 maj 2006 · Naryx Pharma Inc. completed a Series B2 financing of $8 million to advance SPRCAB01, its Phase II nebulized antibiotic for chronic rhinosinusitis. If approved, the tobramycin formulation would be the first drug cleared by the FDA for chronic sinusitis, which is "very different from the simple sinus infection you get after … WitrynaPrior to founding Clinverse, Tim was the Chief Financial Officer of Naryx Pharma, a specialty pharmaceutical company, where he was responsible for all accounting, finance, information systems and a variety of operational functions, and played a key role in Naryxs global patent strategy (with 2 issued patents and 50 patents currently … counterfeit contessa dvd
Naryx Pharma, Inc. - Carpinteria CA and Wilmington DE - Bizapedia
WitrynaNARYX PHARMA, INC. CALIFORNIA STOCK CORPORATION - CA - GENERAL: WRITE REVIEW: Address: 5464 Carpinteria Ave Ste A Carpinteria, CA 93013: Registered Agent: Susan Johnston: Filing Date: August 02, 1999: File Number: 2172504: Contact Us About The Company Profile For Naryx Pharma, Inc. WitrynaA Phase 2, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating the Safety and Efficacy of SPRC-AB01, Tobramycin Solution for Nasal Inhalation, in Post-Surgical Subjects With Chronic Sinusitis Witryna18 kwi 2007 · Naryx Pharma announced that the FDA has granted its request for fast-track designation for SPRC-AB01, ... Naryx is currently conducting a Phase IIb study comparing SPRC-AB01 with placebo in this population of patients. Upcoming Events. 12 Apr. The Participant Playbook Webinar Series, Part 3 — Rethinking the Development … maggiano\\u0027s austin tx